NTLA PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

NTLA ▼ -1.38% at T+5d

NEUTRAL call ✗ call lost -1.38% · α vs SPY +1.37% · entry $13.73 → $13.54

Next anchor: T+20d in 17d

Currently $12.11 · -11.80% from $13.73 entry

Entry anchored
May 29, 03:59 PM ET
via Databento tick

T+1d

-4.37%

call -4.37% · α -4.51%

$13.13

settled 11d ago

T+5d

-1.38%

call -1.38% · α +1.37%

$13.54

settled 5d ago

T+20d

—

call — · α —

—

in 17d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary angioedema will be presented at EAACI 2026. The filing is a pipeline update with no financial results or guidance; the EPS miss of -$0.81 vs -$0.80 consensus is negligible for a pre-revenue biotech.

Actionable Insight

The Phase 3 HAELO data presentation at EAACI is the key catalyst. Positive efficacy/safety data could drive significant upside; negative results would be bearish. Monitor for abstract release and investor reaction post-presentation.

Key Facts

Phase 3 HAELO data for lonvo-z (NTLA-2002) in HAE to be presented at EAACI June 12-15, 2026
Lonvo-z has FDA RMAT, Orphan Drug, and EMA PRIME designations
EPS of -$0.81 vs consensus -$0.80 (1.8% miss) — immaterial for pre-revenue stage
No revenue or guidance reported; company is pre-commercial

Financial Impact

No financial impact; EPS miss of $0.01 is negligible for a pre-revenue biotech

eps

Risk Factors

Phase 3 data may fail to meet efficacy or safety endpoints
Regulatory approval timeline uncertain; competition from existing HAE therapies
Pre-revenue company with high cash burn; dilution risk if financing needed

Market Snapshot

Exchange

Nasdaq

Sector

In Vitro & In Vivo Diagnostic Substances

Analyst Consensus

57% bullish (30 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3304241

10 reports for NTLA

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+1▲ +8.52%Apr 27, 2026

Filters

Reports for NTLA — sortable, filterable
	Type				Now
Jun 1, 2026 11d ago	Press Release NEUTRAL ★ 5/10	$13.73 $13.54	▼ −1.38%	▲ +1.37%	$12.11 (−11.80%)
May 11, 2026 4w ago	8-K MIXED ★ 6/10	$14.42 $12.69	▼ −12.00%	▼ −11.91%	$12.11 (−16.02%)
Apr 27, 2026 6w ago	Press Release BEARISH ★ 6/10	$13.20 $13.87	▼ −5.08%	▼ −3.38%	$12.11 (+8.26%)
Apr 27, 2026 6w ago	8-K BULLISH ★ 8/10	$13.04 $13.87	▲ +6.37%	▲ +5.96%	$12.11 (−7.13%)
Apr 3, 2026 10w ago	Press Release NEUTRAL ★ 2/10	$13.30 $14.26	▲ +7.22%	▲ +3.08%	$12.11 (−8.95%)
Mar 6, 2026 14w ago	Press Release NEUTRAL ★ 3/10	$13.89 $13.38	▼ −3.67%	▼ −2.32%	$12.11 (−12.81%)
Mar 2, 2026 14w ago	Press Release BULLISH ★ 8/10	$15.44 $13.89	▼ −10.04%	▼ −8.83%	$12.11 (−21.57%)
Mar 2, 2026 14w ago	Insider Cluster NEUTRAL ★ 3/10	$15.44 $13.89	▼ −10.04%	▼ −8.83%	$12.11 (−21.57%)
Feb 28, 2026 14w ago	Institutional Cluster NEUTRAL ★ 4/10	$15.44 $13.89	▼ −10.04%	▼ −8.83%	$12.11 (−21.57%)
Feb 26, 2026 15w ago	8-K MIXED ★ 6/10	$14.28 $13.15	▼ −7.91%	▼ −6.79%	$12.11 (−15.20%)

US Market Status

Market Closed — Opens Mon (52h 17m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access